CA Patent

CA2577420A1 — Lonidamine analogues and their use in male contraception and cancer treatment

Assigned to University of Kansas · Expires 2006-03-02 · 20y expired

What this patent protects

Novel compounds useful for inhibiting spermatogenesis and cancer treatment, and in particular as inhibitors of heat shock proteins and/or elongation factor 1 alpha.

USPTO Abstract

Novel compounds useful for inhibiting spermatogenesis and cancer treatment, and in particular as inhibitors of heat shock proteins and/or elongation factor 1 alpha.

Drugs covered by this patent

Patent Metadata

Patent number
CA2577420A1
Jurisdiction
CA
Classification
—
Expires
2006-03-02
Drug substance claim
No
Drug product claim
No
Assignee
University of Kansas
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.